Company intelligence / Profile preview

Shield Holdings

Gateshead, England, United Kingdom

Ownership: Private
Employees: ~63
Development stage: Other

Overview

Commercial-stage company with lead product Accrufer/Feraccru (ferric maltol) approved and launched for iron deficiency treatment in US, EU, UK, and partnered in other regions.[1][4][5]

Therapeutic areas: Hematology
Modalities: Small molecule
Industry: Biotech

Partnerships

Norgine B.V. (EU, UK, Australia, New Zealand)Beijing Aosaikang Pharmaceutical Co., Ltd. (China, Hong Kong, Macau, Taiwan)Korea Pharma Co., Ltd. (South Korea)KYE Pharmaceuticals Inc. (Canada)

Beyond the preview

Go deeper on Shield Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shield Holdings.

Explore the full profile